Text Size
Santen Global

2014 Press Release

RSS

Press Release

Santen Launches TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension
Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Diabetic Macular Edema (DME), its Fourth Indication
Santen and Singapore Eye Research Institute (SERI) Announce a Collaboration to Develop New Ophthalmic Therapeutics
Santen Receives Financing from the Development Bank of Japan based on "DBJ Environmental Rating"
Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck
Increase of Capital for a Consolidated Subsidiary in Europe
Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Myopic Choroidal Neovascularization (mCNV)
Eyestrain Common Issue Caused by Contact Lenses!? Santen Launches Soft Santear Hitomi Stretch, an Eye Drop for Use with Soft Contact Lenses to Reduce Eyestrain by Relaxing Ciliary Muscle Stiffness Which Can Be a Cause of Eyestrain
Notice on Details of the Rights to Subscribe for New Shares (Stock Options as Stock-Linked Remuneration)
Santen Files for Manufacturing/Marketing Approval of its Glaucoma and Ocular Hypertension Therapeutic, COSOPT Mini Combination Ophthalmic Solution
Santen to Grant Rights to Subscribe for New Shares as Stock Options as Stock-Linked Remuneration
Medium-Term Management Plan FY2014-2017
Changes in Significant Shareholders
Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck
Notice of the Nominations for the Member of the Board
Santen Announces Financial Results for the Year ended March 31, 2014
Santen Announces the Signing of Agreement between Merck for the Purchase of Assets in Ophthalmology
Santen Phase III Study Meets Primary Endpoint for The treatment of Non-Infectious Posterior Segment Uveitis (NI-PSU)
Santen Partners with Akorn, Inc. subsidiary Oak Pharmaceuticals for Marketing of Tafluprost, the Treatment of Glaucoma and Ocular Hypertension in the U.S.
The Osaka Study: An epidemiological survey showing that dry eye disease lowers work productivity, affects quality of life and correlates with metabolic syndrome
Notice of the appointment of Corporate Officers
Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology
Changes in Significant Shareholders
Santen Pharmaceutical Voluntarily Adopts International Financial Reporting Standards (IFRS)
Revision of consolidated earnings forecasts for FY 2013
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved